The first biosimilar to receive FDA approval is now available the United States.
Davy James, Managing Editor of Specialty Pharmacy Times
Advertisement
Articles by Davy James, Managing Editor of Specialty Pharmacy Times
The FDA today approved evolocumab (Repatha) injection, a new treatment for patients unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.
Advertisement
Latest Updated Articles
Second PCSK9 Repatha Approved by FDAPublished: August 27th 2015 | Updated:
First Biosimilar Filgrastim Launched TodayPublished: September 3rd 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nerandomilast Receives FDA Approval for Idiopathic Pulmonary Fibrosis
2
Study Shows Infliximab Biosimilar is Safe in Patients Undergoing RA Treatment
3
Dexamethasone-Sparing Regimen Offers Safer Option for Frail Patients With MM
4
Pneumococcal Polysaccharide Vaccination Does Not Reduce Rates of Cardiovascular Events
5
